Resources Repository
-
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Operations Research | Technology Assessment | Cost-Effectiveness Analysis | Health Outcomes | Health/Medicine | Business/Industry | Chronic Disease/Risk | Preferences/Values | Priority Setting/Ethics | Costing Methods | Value of Information | Mathematical Models | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Health Systems | Policy/Regulation | Economics/Finance | Science/Technology | Global -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Technology Assessment | Cost-Effectiveness Analysis | Health/Medicine | Business/Industry | Chronic Disease/Risk | Preferences/Values | Priority Setting/Ethics | Evidence Synthesis | Value of Information | Infectious Diseases | Mental Health | Health Systems | Economics/Finance | Government/Law | Science/Technology | North America | Europe -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Technology Assessment | Cost-Effectiveness Analysis | Decision Analysis | Health Outcomes | Health/Medicine | Chronic Disease/Risk | Costing Methods | Test Performance | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Science/Technology | North America -
OrganizationWeb Portal 2024One Health Trust
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded …
One Health Trust, formally the Center for Disease Dynamics, Economics & Policy (CDDEP), was founded with the objective of using research to support better decision-making in health policy. One Health Trust researchers employ a range of expertise—including economics, epidemiology, disease modeling, risk analysis, and statistics—to conduct actionable, policy-oriented research on malaria, antibiotic resistance, disease control priorities, environmental health, alcohol and tobacco, and other global health priorities. One Health Trust projects are global in scope, spanning…
Technology Assessment | Cost-Effectiveness Analysis | Health Outcomes | Health/Medicine | Chronic Disease/Risk | Costing Methods | Mathematical Models | Infectious Diseases | Social Determinants | Environmental Health | Policy/Regulation | Climate/Environment | Economics/Finance | Global | Sub-Saharan Africa | Asia & Pacific -
ArticlePublication 2016Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to …
Timely implementation of recommended interventions can provide health benefits to patients and cost savings to the health service provider. Effective approaches to increase the implementation of guidance are needed. Since investment in activities that improve implementation competes for funding against other health generating interventions, it should be assessed in term of its costs and benefits. In 2010, the National Institute for Health and Care Excellence released a clinical guideline recommending natriuretic peptide (NP) testing in…
Operations Research | Cost-Effectiveness Analysis | Health Outcomes | Health/Medicine | Chronic Disease/Risk | Health Systems | Clinical Care | Economics/Finance | Europe -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Cost-Effectiveness Analysis | Calibration/Validation | Health Outcomes | Health/Medicine | Chronic Disease/Risk | Mathematical Models | Infectious Diseases | Health Systems | Global | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2024Extended Cost-Effectiveness Analysis of Interventions to Improve Uptake of Diabetes Services in South Africa
This study examines the potential impact of a conditional cash transfer (CCT) program on diabetes …
This study examines the potential impact of a conditional cash transfer (CCT) program on diabetes diagnosis and treatment service utilization in South Africa (SA) using extended cost-effectiveness analysis (ECEA). Applying a Markov model over a 45-year period, the analysis compares costs, health benefits, and financial risk protection (FRP) attributes of different CCT strategies, drawing from SA-specific data. Three scenarios were simulated: covering diagnosis services only, treatment services only, and both diagnosis and treatment services. Cost-effectiveness,…
Cost-Effectiveness Analysis | Health Outcomes | Health/Medicine | Chronic Disease/Risk | Mathematical Models | Policy/Regulation | Sub-Saharan Africa -
ArticlePublication 2021Alleviating the Burden of Diabetes with Health Equity Funds: Economic Evaluation of the Health & Financial Risk Protection Benefits in Cambodia
This study examines the potential distributional health and financial impacts of implementing strategies to provide …
This study examines the potential distributional health and financial impacts of implementing strategies to provide financial coverage for diabetes services through Health Equity Funds (HEF) in Cambodia. Utilizing a Markov model, the trajectory of diabetes is projected over a 45-year period to estimate societal costs, health outcomes, and individual out-of-pocket expenditures associated with six HEF coverage strategies. Input parameters are derived from published literature and household survey data. Strategies covered different combinations of types of…
Cost-Effectiveness Analysis | Health Outcomes | Health/Medicine | Chronic Disease/Risk | Mathematical Models | Asia & Pacific -
ArticlePublication 2019Cost-Effectiveness of U.S. National SSB Tax with a Multistakeholder Approach: Who Pays and Who Benefits
This analysis estimated the health impact and cost-effectiveness of a national penny-per-ounce sugar-sweetened beverage (SSB) …
This analysis estimated the health impact and cost-effectiveness of a national penny-per-ounce sugar-sweetened beverage (SSB) tax, overall and with stratified costs and benefits for nine distinct stakeholder groups. A microsimulation model (CVD PREDICT) was used to estimate cardiovascular disease reductions, quality-adjusted life years gained, and cost-effectiveness for U.S. adults aged 35 to 85 years, evaluating full and partial consumer price pass-through. Results showed that from both a health care and societal perspective, the SSB tax was…
Cost-Effectiveness Analysis | Health/Medicine | Business/Industry | Chronic Disease/Risk | Microsimulation | Policy/Regulation | Economics/Finance | Government/Law | North America